Prediction of Type 2 Diabetes Remission after Bariatric or Metabolic Surgery

Bariatric surgery has evolved from a surgical measure for treating morbid obesity to an epochal remedy for treating metabolic syndrome as a whole, which is represented by type 2 diabetes mellitus.Numerous clinical trials have advocated bariatric or metabolic surgery over nonsurgical interventions because of markedly superior metabolic outcomes in morbidly obese patients who satisfy traditional criteria for bariatric surgery (body mass index [BMI] >35 kg/m 2 ) and in less obese or simply overweight patients.Nevertheless, not all diabetes patients achieve the most desirable outcomes; i.e., diabetes remission after metabolic surgery.Thus, candidates for metabolic surgery should be carefully selected based on comprehensive preoperative assessments of the risk-benefit ratio.Predictors for diabetes remission after metabolic surgery may be classified into two groups based on mechanism of action.The first is indices for preserved pancreatic beta-cell function, including younger age, shorter duration of diabetes, and higher C-peptide level.The second is the potential for an insulin resistance reduction, including higher baseline BMI and visceral fat area.Several prediction models for diabetes remission have been suggested by merging these two to guide the joint decision-making process between clinicians and patients.Three such models, DiaRem, ABCD, and individualized metabolic surgery scores, provide an intuitive scoring system and have been validated in an independent external cohort and can be utilized in routine clinical practice.These prediction models need further validation in various ethnicities to ensure universal applicability.